The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia

The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia

Tumour hypoxia reduces the efficacy of radiotherapy. Starting from a drug screen, here the authors demonstrate that the anti-malarial, atovaquone, reduces the oxygen consumption rate of cancer cells by inhibition of mitochondrial complex III and sensitises to radiotherapy by reducing tumour hypoxia.

Bibliographic Details
Main Authors: Thomas M. Ashton, Emmanouil Fokas, Leoni A. Kunz-Schughart, Lisa K. Folkes, Selvakumar Anbalagan, Melanie Huether, Catherine J. Kelly, Giacomo Pirovano, Francesca M. Buffa, Ester M. Hammond, Michael Stratford, Ruth J. Muschel, Geoff S. Higgins, William Gillies McKenna
Format: Article
Language:English
Published: Nature Publishing Group 2016-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms12308

Internet

https://doi.org/10.1038/ncomms12308

Similar Items